Abstract 1153P
Background
The rapidly developing field of immune checkpoint inhibitors (ICI) necessitates insights in long-term adverse events (AE), like ICI related adrenal insufficiency (irAI). In meta-analyses of clinical trials, primary AI (PAI) incidence is likely overestimated (4-7% for combination ICI), as PAI and secondary AI (SAI) are rarely distinguished.
Methods
In this monocenter, pan-cancer retrospective analysis, patients with a single malignancy who received anti-PD-(L)1 and/or anti-CTLA-4 therapy before September 10th 2021 and received (hydro/fludro)cortisone were identified. irAI was considered when AI was diagnosed in the absence of adrenal metastases, -surgery, -radiotherapy and long-term corticosteroid use. Diagnosis of PAI was based on cortisol <13 μmol/l and ACTH >60 ng/l, synacthen test and/or presence of mineral-corticoid dysfunction. SAI was diagnosed when ACTH <60 ng/l with low cortisol or in case of confirmed hypophysitis. Other irAI cases were labeled as unknown origin.
Results
Of 4314 patients with ICI, 160 (3.7%) developed irAI, consisting almost exclusively of SAI (3.1%) rather than PAI (0.05%, P<.001). irAI incidence was significantly higher for combination treatment versus anti-PD-(L)1 monotherapy (OR 4.95, 95% CI 3.55-6.97, p<.001). SAI presented as hypophysitis in 38% and as isolated adrenal deficiency in 62% of cases. Age, gender, metastatic status of the malignancy, history of endocrine or autoimmune disorder and other grade 3-4 AEs did not differ between PAI and SAI, or hypophysitis and IAD cases. Table: 1153P
Incidence of immunotherapy related adrenal insufficiency
Anti-PD-(L)1 | Anti-CTLA-4 | Combination anti-PD-1 + anti-CTLA-4 | Total | |
Melanoma | 3.8% 29/768 | 3.1% 10/326 | 11.1% 59/533 | 6.7% 98/1466 |
Lung cancer | 1.0% 12/1199 | 0 | 4.5% 2/44 | 1.1% 14/1243 |
Urethral and renal cancer | 1.2% 3/246 | 0% 0/1 | 10.6% 15/142 | 4.6% 18/395 |
Breast cancer | 2.0% 5/254 | 0 | 14.3% 2/14 | 2.6% 7/268 |
Colorectal cancer | 2.4% 2/85 | 0 | 3.7% 4/108 | 3.1% 6/193 |
Bladder cancer | 3.6% 4/111 | 0% 0/10 | 10.0% 5/50 | 5.4% 9/168 |
Other | 0.6% 3/484 | 0% 0/2 | 5.0%5/101 | 1.4% 8/581 |
Total | 1.8% 58/3147 | 2.9% 10/339 | 9.3% 92/992 | 3.7% 160/4314 |
Conclusions
In contrast to what is suggested in trials, ICI-induced primary adrenal insufficiency was extremely rare in this real-world analysis, while secondary adrenal insufficiency was dominantly prevalent. Combination therapy leads more frequently to irAI. In conclusion, an improved understanding of irAI is needed, which may lead to improved diagnosis, and is essential for the development of predictive biomarkers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E. Kapiteijn: Financial Interests, Institutional, Advisory Board: BMS, Novartis, Pierre Fabre, Merck, Delcath, Bayer, Lilly; Financial Interests, Institutional, Coordinating PI: BMS, Pierre Fabre, Delcath. C.U. Blank: Financial Interests, Institutional, Advisory Board: BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre; Financial Interests, Personal, Advisory Board: Third Rock Ventures; Financial Interests, Personal, Stocks/Shares: Immagene; Financial Interests, Institutional, Coordinating PI: NanoString, BMS, Novartis, 4SC; Financial Interests, Personal, Stocks/Shares, intention to develop IFN signature algorithm: NewCo, no name yet; Other, pending patent: WO 2021/177822 A1. All other authors have declared no conflicts of interest.
Resources from the same session
1160P - Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight-adjusted dose, FLATIMEL study
Presenter: Iona Campo le Brun
Session: Poster session 13
1161P - Therapeutic outcome of molecular profiling of melanoma patients resistant to standard treatment: Real-world data
Presenter: Madona SAKKAL
Session: Poster session 13
1162P - Prolonged exposure to proton pump inhibitors (PPI) at the time of initiation of immune checkpoint blockade (ICB) mediates better clinical outcomes in patients with metastatic melanoma
Presenter: Kyrillus Shohdy
Session: Poster session 13
1163P - CD39 affect the prognostic role of NLR via N2 neutrophils in metastatic melanoma patients treated with immunotherapy
Presenter: Domenico Mallardo
Session: Poster session 13
1164P - Changes of TCR repertoire in metastatic melanoma and renal cell carcinoma patients treated with nivolumab correlate with overall survival
Presenter: Martin Klabusay
Session: Poster session 13
1165P - Single cell spatial features of in-transit melanoma associated with patient outcome to immunotherapy
Presenter: Xinyu Bai
Session: Poster session 13
1166P - Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary melanoma to in-transit and distant metastasis
Presenter: Giuseppe Tarantino
Session: Poster session 13
1168P - Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined
Presenter: Jan-Malte Placke
Session: Poster session 13
1169P - Tumour transcriptional and spatial protein profiling in Mexican patients reveals that acral lentiginous melanoma is characterized by an immunosuppressive microenvironment
Presenter: Martha Estefania Vázquez-Cruz
Session: Poster session 13
1170P - Survival outcome prediction of primary melanoma tumours from histology images using deep learning
Presenter: Céline Bossard
Session: Poster session 13